Explore this research category across breast cancer datasets
| RNA Name | Mechanism of Action | Effect on Cancer | Cancer Type | Reference |
|---|---|---|---|---|
|
SAT1
mRNA |
p53?responsive polyamine catabolic enzyme linked to lipid peroxidation (e.g., via ALOX15 pathway). | In TNBC cells, SBFI26 elevates SAT1 expression during ferroptosis induction. | Breast Cancer |
PubMed
Reference PMID: 38516826 |
|
BRCA1
mRNA |
BRCA1 loss creates a vulnerability to ferroptosis; GPX4/PARP co-inhibition exploits ferroptotic susceptibility of BRCA1-deficient tumors. | BRCA1-deficient TNBC models show heightened sensitivity to GPX4 inhibition (and PARP+GPX4 co-targeting), indicating enhanced ferroptosis. | Breast Cancer |
PubMed
Reference PMID: 38552003 |
|
MTOR
mRNA |
Inhibition of mTORC1 (downstream of MTOR) reduces SREBP1/SCD1 lipid synthesis, shifting lipids toward ferroptosis?prone species and triggering ferroptosis. | Blocking mTORC1 signaling sensitizes TNBC cells to ferroptosis; formononetin triggers ferroptosis via mTORC1/SREBP1/SCD1 axis in TNBC. | Breast Cancer |
PubMed
Reference PMID: 39399463 |
|
FADS1
mRNA |
Desaturase shaping PUFA content; modulates availability of peroxidation substrates for ferroptosis. | FADS1/2?high TNBC subtype is more susceptible to ferroptosis?inducing agents. | Breast Cancer |
PubMed
Reference PMID: 38926633 |
|
EGR1
mRNA |
EGR1 upregulation triggers ferroptosis by repressing NRF2�HMOX1 antioxidant axis and elevating lipid ROS in TNBC lines (MDA?MB?231/?468). | Promotes ferroptosis; inhibits TNBC cell viability and tumor growth in models. | Breast Cancer |
PubMed
Reference PMID: 27377973 |
|
NCOA4
mRNA |
Cargo receptor mediating ferritinophagy; releases Fe2+ to fuel ferroptosis. | Sulforaphene inhibits TNBC by activating Egr1 | Breast Cancer |
PubMed
Reference PMID: 39353532 |
|
CAV1
mRNA |
Caveolin?1 increases IFNGR1, amplifying IFN? signaling to inhibit system Xc? (SLC7A11), thereby promoting lipid peroxidation and ferroptosis. | Overexpression of CAV1 promotes ferroptosis and suppresses breast tumor growth; study used TNBC cells (e.g., MDA?MB?231). | Breast Cancer |
PubMed
Reference PMID: 39395272 |
|
VDAC1
mRNA |
VDAC1 oligomerization on mitochondria promotes mitochondrial ROS release required for cysteine-deprivation/RSL3-induced ferroptosis. | In MDA?MB?231/?468 TNBC cells, blocking VDAC1 oligomerization reduces ferroptosis; VDAC1 activity promotes ferroptosis. | Breast Cancer |
PubMed
Reference PMID: 39521767 |
|
ELAVL1
mRNA |
HuR (ELAVL1) inhibition reduces SLC7A11 and engages ferroptosis among multiple PCDs in breast cancer cells incl. MDA?MB?231 | ELAVL1 activity supports antioxidant defenses; its inhibition promotes ferroptosis and impairs TNBC cell growth (shown in MDA?MB?231) | Breast Cancer |
PubMed
Reference PMID: 39627778 |
|
PRKAA2
mRNA |
AMPK activation (by CAPE) promotes ROS/lipid peroxidation and downregulates GPX4/ferritin, inducing ferroptosis. | Activation of AMPK triggers ferroptosis and suppresses TNBC growth in cell/xenograft models. | Breast Cancer |
PubMed
Reference PMID: 39729481 |